Free Trial
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
uniQure N.V. stock logo
QURE
uniQure
$22.59
+0.2%		$41.57
$8.73
▼
$71.50
$1.56B1.063.49 million shs2.05 million shs
Rezolute, Inc. stock logo
RZLT
Rezolute
$4.87
+5.0%		$4.46
$1.07
▼
$11.46
$448.82M0.531.83 million shs1.87 million shs
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
$16.99
+0.5%		$19.03
$12.99
▼
$25.59
$1.50B0.421.90 million shs1.46 million shs
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
$24.74
+3.3%		$29.43
$20.32
▼
$40.22
$1.55B1.261.01 million shs918,952 shs
10 Best Stocks to Own in Fall 2026 Cover
10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
uniQure N.V. stock logo
QURE
uniQure
+0.22%-3.71%-50.89%-47.01%-62.33%
Rezolute, Inc. stock logo
RZLT
Rezolute
+4.96%+21.45%+19.95%+2.53%-44.15%
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
+0.53%-3.47%-14.36%-28.04%+2.97%
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
+3.30%-3.43%-17.31%-21.16%-18.89%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
uniQure N.V. stock logo
QURE
uniQure
$22.59
+0.2%		$41.57
$8.73
▼
$71.50
$1.56B1.063.49 million shs2.05 million shs
Rezolute, Inc. stock logo
RZLT
Rezolute
$4.87
+5.0%		$4.46
$1.07
▼
$11.46
$448.82M0.531.83 million shs1.87 million shs
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
$16.99
+0.5%		$19.03
$12.99
▼
$25.59
$1.50B0.421.90 million shs1.46 million shs
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
$24.74
+3.3%		$29.43
$20.32
▼
$40.22
$1.55B1.261.01 million shs918,952 shs
10 Best Stocks to Own in Fall 2026 Cover
10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
uniQure N.V. stock logo
QURE
uniQure
+0.22%-3.71%-50.89%-47.01%-62.33%
Rezolute, Inc. stock logo
RZLT
Rezolute
+4.96%+21.45%+19.95%+2.53%-44.15%
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
+0.53%-3.47%-14.36%-28.04%+2.97%
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
+3.30%-3.43%-17.31%-21.16%-18.89%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
uniQure N.V. stock logo
QURE
uniQure
2.75
Moderate Buy$53.73137.84% Upside
Rezolute, Inc. stock logo
RZLT
Rezolute
2.79
Moderate Buy$11.22130.44% Upside
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
2.82
Moderate Buy$41.80146.03% Upside
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
2.82
Moderate Buy$44.2578.86% Upside

Current Analyst Ratings Breakdown

Latest RZLT, STOK, QURE, and SNDX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/6/2026
Rezolute, Inc. stock logo
RZLT
Rezolute
Lake Street Capital logo
Lake Street Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$9.00 ➝ $12.00
10/6/2026
Rezolute, Inc. stock logo
RZLT
Rezolute
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
10/6/2026
Rezolute, Inc. stock logo
RZLT
Rezolute
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetMarket Outperform$11.00 ➝ $15.00
10/5/2026
Rezolute, Inc. stock logo
RZLT
Rezolute
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeNeutral ➝ Overweight
10/5/2026
uniQure N.V. stock logo
QURE
uniQure
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight$60.00 ➝ $28.00
10/2/2026
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
10/2/2026
uniQure N.V. stock logo
QURE
uniQure
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$65.00 ➝ $48.00
10/1/2026
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
10/1/2026
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/30/2026
uniQure N.V. stock logo
QURE
uniQure
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetNeutral$46.00 ➝ $31.00
9/30/2026
Rezolute, Inc. stock logo
RZLT
Rezolute
Lake Street Capital logo
Lake Street Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$9.00
(Data available from 10/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
uniQure N.V. stock logo
QURE
uniQure
$16.10M97.33N/AN/A$3.19 per share7.08
Rezolute, Inc. stock logo
RZLT
Rezolute
N/AN/AN/AN/A$1.05 per shareN/A
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
$172.35M8.74N/AN/A$0.74 per share22.96
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
$184.42M8.66N/AN/A$6.17 per share4.01
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
uniQure N.V. stock logo
QURE
uniQure
-$198.97M-$4.01N/AN/AN/A-1,350.73%-111.96%-29.01%11/9/2026 (Estimated)
Rezolute, Inc. stock logo
RZLT
Rezolute
-$77.59M-$0.76N/AN/AN/AN/A-62.99%-57.94%11/5/2026 (Estimated)
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
-$285.42M-$2.51N/AN/AN/A-87.52%-372.94%-39.11%11/2/2026 (Estimated)
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
-$6.89M-$3.34N/AN/AN/A-753.60%-59.36%-51.46%11/3/2026 (Estimated)

Latest RZLT, STOK, QURE, and SNDX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q1 2027
Rezolute, Inc. stock logo
RZLT
Rezolute
-$0.18N/AN/AN/A$1.12 millionN/A
11/3/2026Q3 2026
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
-$0.88N/AN/AN/A$8.21 millionN/A
11/2/2026Q3 2026
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
-$0.4793N/AN/AN/A$82.41 millionN/A
9/24/2026Q4 2026
Rezolute, Inc. stock logo
RZLT
Rezolute
-$0.1479-$0.20-$0.0522-$0.20N/AN/A
8/4/2026Q2 2026
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
-$0.4477-$0.55-$0.1023-$0.55$79.36 million$72.79 million
8/3/2026Q2 2026
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
-$0.7950-$0.93-$0.1350-$0.93$4.89 million$9.33 million
7/29/2026Q2 2026
uniQure N.V. stock logo
QURE
uniQure
-$0.8223-$1.22-$0.3977-$1.22$5.45 million$5.84 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
uniQure N.V. stock logo
QURE
uniQure
N/AN/AN/AN/AN/A
Rezolute, Inc. stock logo
RZLT
Rezolute
N/AN/AN/AN/AN/A
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
N/AN/AN/AN/AN/A
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
uniQure N.V. stock logo
QURE
uniQure
0.15
10.01
10.01
Rezolute, Inc. stock logo
RZLT
Rezolute
N/A
9.68
9.68
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
38.95
6.77
6.44
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
N/A
7.69
7.69

Institutional Ownership

CompanyInstitutional Ownership
uniQure N.V. stock logo
QURE
uniQure
78.83%
Rezolute, Inc. stock logo
RZLT
Rezolute
82.97%
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
N/A
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
uniQure N.V. stock logo
QURE
uniQure
4.65%
Rezolute, Inc. stock logo
RZLT
Rezolute
14.78%
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
4.80%
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
9.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
uniQure N.V. stock logo
QURE
uniQure
22169.37 million66.14 millionOptionable
Rezolute, Inc. stock logo
RZLT
Rezolute
5896.73 million82.43 millionOptionable
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
29888.61 million84.36 millionOptionable
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
17064.53 million58.33 millionOptionable

Recent News About These Companies

FDA Alignment on Zorevunersen Endpoints Could Be A Game Changer For Stoke Therapeutics (STOK)
 |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/fda-alignment-zorevunersen-endpoints-could-230942770.html
Stoke Therapeutics, Inc. Announces Presentations of Data for Stk-002 At the American Academy of Ophthalmology 2026 Annual Meeting
October 6, 2026  |  marketscreener.comM
Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of ...
October 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/stoke-therapeutics-announces-presentations-stk-120000821.html
Stoke Therapeutics (NASDAQ:STOK) Shares Down 5.9% - What's Next?
October 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-stoke-therapeutics-nasdaq-stok-shares-down-59-whats-next-2026-10-06/
Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting
October 6, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261001196435/en/stoke-therapeutics-announces-presentations-of-stk-002-an-investigational-medicine-for-the-treatment-of-autosomal-dominant-optic-atrophy-adoa-at-the-american-academy-of-ophthalmology-aao-2026-annual-meeting/
Stoke Therapeutics, Inc. Announces Completion Of Successful Meeting With The FDA To Align On Planned U.S. NDA For Zorevunersen
October 5, 2026  |  marketscreener.comM
Stoke Therapeutics stock heads into November 3 results below key averages
October 5, 2026  |  ad-hoc-news.deA
Stoke Therapeutics Completes FDA Meeting on Planned Zorevunersen NDA
October 5, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/stoke-therapeutics-completes-fda-meeting-121300798.html
Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of ...
October 5, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/stoke-therapeutics-announces-completion-successful-110000858.html
Stoke Therapeutics (NASDAQ:STOK) General Counsel Jonathan Allan Sells 627 Shares of Stock
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31083021
Stoke Therapeutics (NASDAQ:STOK) Insider Barry Ticho Sells 1,051 Shares of Company Stock
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31083003
Stoke Therapeutics (NASDAQ:STOK) General Counsel Sells 627 Shares of Stock
October 3, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-stok-insider-buying-and-selling-2026-10-03/
Stoke Therapeutics (NASDAQ:STOK) Stock: Insider Jonathan Allan Sells 627 Shares
October 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-stoke-therapeutics-nasdaq-stok-stock-insider-jonathan-allan-sells-627-shares-2026-10-02/
Stoke Therapeutics (NASDAQ:STOK) Insider Sells 1,051 Shares of Stock
October 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-stoke-therapeutics-nasdaq-stok-insider-sells-1051-shares-of-stock-2026-10-02/
Bank of America Corp DE Makes New Investment in Stoke Therapeutics, Inc. $STOK
September 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-makes-new-investment-in-stoke-therapeutics-inc-stok-2026-09-27/
Stoke Therapeutics, Inc. Announces Board Changes
September 23, 2026  |  marketscreener.comM
Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval ...
September 23, 2026  |  marketscreener.comM
Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization
September 23, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260923239117/en/stoke-therapeutics-appoints-bo-cumbo-to-its-board-of-directors-enhancing-commercial-expertise-as-the-company-advances-zorevunersen-development-toward-potential-fda-approval-and-commercialization/
Stoke Therapeutics (NASDAQ:STOK) Shares Down 9% - What's Next?
September 23, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-stoke-therapeutics-nasdaq-stok-shares-down-9-whats-next-2026-09-23/
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of "Moderate Buy" from Analysts
September 23, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-stoke-therapeutics-inc-nasdaq-stok-receives-average-rating-of-moderate-buy-from-analysts-2026-09-23/
Stoke Therapeutics stock holds gains after recent data update
September 19, 2026  |  ad-hoc-news.deA

New MarketBeat Followers Over Time

Media Sentiment Over Time

uniQure stock logo

uniQure NASDAQ:QURE

$22.59 +0.05 (+0.22%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$22.54 -0.05 (-0.22%)
As of 10/9/2026 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Rezolute stock logo

Rezolute NASDAQ:RZLT

$4.87 +0.23 (+4.96%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$4.87 +0.00 (+0.06%)
As of 10/9/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Syndax Pharmaceuticals stock logo

Syndax Pharmaceuticals NASDAQ:SNDX

$16.99 +0.09 (+0.53%)
As of 10/9/2026 04:00 PM Eastern

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Stoke Therapeutics stock logo

Stoke Therapeutics NASDAQ:STOK

$24.74 +0.79 (+3.30%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$24.74 0.00 (0.00%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas